Inspire Medical Systems Reports Q3 2026 Results; Key Test for Stabilization Thesis

What happened

Inspire Medical Systems released its third-quarter 2026 financial results on November 2, 2026, covering the quarter ended September 30, 2026. The announcement follows a turbulent 2025 in which management cut guidance amid GLP-1 competition and a slow Inspire V transition, but also secured a roughly 50% Medicare facility fee increase effective January 2026. The Q3 2026 figures will show whether revenue growth re-accelerated toward the 10-13% base case and whether gross margin held at or above 84-86%, as outlined in the prior DeepValue report. Investor attention will focus on procedure volume trends, the impact of the reimbursement uplift, and any commentary on GLP-1 cannibalization or payer dynamics. The company's ability to meet or exceed lowered expectations will determine whether the stock's derating since early 2025 has created an attractive entry or reflects a structurally impaired growth profile.

Implication

For investors, the key is whether the report validates the base case of 10-13% revenue growth and stable high margins. Strong execution, with procedure volumes benefiting from reimbursement and limited GLP-1 erosion, would justify adding on weakness toward $90 and targeting $120-135. Conversely, if revenue growth falls into single digits or gross margin dips below 84%, the bear scenario gains credence, and positions should be trimmed or exited. The DOJ investigation and GLP-1 adoption remain critical risks that could resurface in commentary. Monitor management's 2027 guidance and any updates on Inspire V penetration and international expansion.

Thesis delta

The thesis remains broadly intact but hinges on the Q3 2026 data. Positive results would strengthen the bull case and support the potential buy rating; negative results would shift the probability toward the bear scenario and likely reduce conviction. The Medicare reimbursement uplift and Inspire V efficiency gains are still the primary upside catalysts, but they must materialize in the numbers.